Theratechnologies Inc. Total Liabilities
Theratechnologies Inc. total liabilities. Based on the latest financial reports, Theratechnologies Inc. (TH) has total liabilities worth CA$79.19 Million CAD (≈ $57.29 Million USD) as of May 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Theratechnologies Inc. liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Theratechnologies Inc. (1996–2024)
Total liabilities of Theratechnologies Inc. from 1996 to 2024. This chart illustrates how Theratechnologies Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore TH long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Theratechnologies Inc. Competitors by Total Liabilities
The table below lists competitors of Theratechnologies Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Imagesat International ISI Ltd
TA:ISI
|
Israel | ILA76.08 Million |
|
Cheng Fwa Industrial Ltd
TWO:5426
|
Taiwan | NT$871.70 Million |
|
Korea Real Estate Investment & Trust Co Ltd
KO:034830
|
Korea | ₩968.23 Billion |
|
UniTest Incorporation
KQ:086390
|
Korea | ₩79.12 Billion |
|
Gala Precision Engineering
NSE:GALAPREC
|
India | Rs819.80 Million |
|
Bank Agris Tbk
JK:AGRS
|
Indonesia | Rp16.70 Trillion |
|
PChome Online
TWO:8044
|
Taiwan | NT$23.50 Billion |
|
Promate Solutions
TWO:6577
|
Taiwan | NT$677.25 Million |
Liability Composition Analysis (1996–2024)
This chart breaks down Theratechnologies Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see TH asset base.
Liquidity & Leverage Metrics
Theratechnologies Inc. Total Liabilities Ratios Explained
Theratechnologies Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.01 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Theratechnologies Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Theratechnologies Inc. (1996–2024)
The table below shows the annual total liabilities of Theratechnologies Inc. from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-11-30 | CA$78.61 Million ≈ $56.87 Million |
-20.30% |
| 2023-11-30 | CA$98.64 Million ≈ $71.35 Million |
-14.84% |
| 2022-11-30 | CA$115.83 Million ≈ $83.79 Million |
+14.17% |
| 2021-11-30 | CA$101.45 Million ≈ $73.39 Million |
+4.68% |
| 2020-11-30 | CA$96.92 Million ≈ $70.11 Million |
+4.53% |
| 2019-11-30 | CA$92.72 Million ≈ $67.07 Million |
+21.68% |
| 2018-11-30 | CA$76.20 Million ≈ $55.12 Million |
+195.60% |
| 2017-11-30 | CA$25.78 Million ≈ $18.65 Million |
+32.78% |
| 2016-11-30 | CA$19.41 Million ≈ $14.04 Million |
-13.64% |
| 2015-11-30 | CA$22.48 Million ≈ $16.26 Million |
+3.89% |
| 2014-11-30 | CA$21.64 Million ≈ $15.65 Million |
+263.74% |
| 2013-11-30 | CA$5.95 Million ≈ $4.30 Million |
-56.74% |
| 2012-11-30 | CA$13.75 Million ≈ $9.95 Million |
-14.08% |
| 2011-11-30 | CA$16.01 Million ≈ $11.58 Million |
-14.08% |
| 2010-11-30 | CA$18.63 Million ≈ $13.48 Million |
-25.46% |
| 2009-11-30 | CA$25.00 Million ≈ $18.08 Million |
+331.28% |
| 2008-11-30 | CA$5.80 Million ≈ $4.19 Million |
-32.67% |
| 2007-11-30 | CA$8.61 Million ≈ $6.23 Million |
+51.34% |
| 2006-11-30 | CA$5.69 Million ≈ $4.11 Million |
+43.21% |
| 2005-11-30 | CA$3.97 Million ≈ $2.87 Million |
-5.60% |
| 2004-11-30 | CA$4.21 Million ≈ $3.04 Million |
-49.87% |
| 2003-11-30 | CA$8.39 Million ≈ $6.07 Million |
-18.27% |
| 2002-11-30 | CA$10.27 Million ≈ $7.43 Million |
-47.14% |
| 2001-11-30 | CA$19.43 Million ≈ $14.05 Million |
+18.05% |
| 2000-11-30 | CA$16.46 Million ≈ $11.91 Million |
+1001.62% |
| 1999-11-30 | CA$1.49 Million ≈ $1.08 Million |
-0.23% |
| 1998-11-30 | CA$1.50 Million ≈ $1.08 Million |
+1.47% |
| 1997-11-30 | CA$1.48 Million ≈ $1.07 Million |
-66.86% |
| 1996-11-30 | CA$4.45 Million ≈ $3.22 Million |
-- |
About Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatm… Read more